Journal of Yeungnam Medical Science

Yeungnam University College of Medicine, Yeungnam University Institute Medical Science (영남대 의대 학술지 편집위원회)
권호 표지
DOI QR코드

DOI QR Code

Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for patient with leptomeningeal metastasis of epidermal growth factor receptor mutant non-small cell lung cancer

  • Lee, Jong Sik (Department of Internal Medicine, Konkuk University School of Medicine) ;
  • Lee, Kyung Ann (Department of Internal Medicine, Konkuk University School of Medicine) ;
  • Lee, Kang Hoon (Department of Internal Medicine, Konkuk University School of Medicine) ;
  • Moon, Sun Young (Department of Internal Medicine, Konkuk University School of Medicine) ;
  • Kim, In Ae (Department of Internal Medicine, Konkuk University School of Medicine) ;
  • Jeon, Sung Jin (Department of Internal Medicine, Konkuk University School of Medicine) ;
  • Min, Jae Ki (Department of Internal Medicine, Konkuk University School of Medicine) ;
  • Kim, Hee Joung (Department of Internal Medicine, Konkuk University School of Medicine) ;
  • Lee, Kye Young (Department of Internal Medicine, Konkuk University School of Medicine)
  • Received : 2014.12.23
  • Accepted : 2015.04.21
  • Published : 2016.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

We report on a 64-year-old man with leptomeningeal metastasis (LM) from an epidermal growth factor receptor (EGFR)-mutated adenocarcinoma of the lung. He was treated with paclitaxel, cisplatin. After completion of chemotherapy, he complained of headache, nausea, and vomiting. EGFR-mutated tumor cells were identified from the cerebrospinal fluid (CSF). Second-line therapy with gefitinib, methotrexate was started. After receiving gefitinib for 4 weeks, he had no more headaches or vomiting. Eleven months after initiation of gefitinib, he developed headache and nausea. Chest computed tomography showed aggravation of bone metastasis. Third-line therapy was started with gemcitabine and carboplatin. Two weeks later, he experienced disorientation. After a fourth relapse within the central nervous system, the therapy was switched to erlotinib and significant improvement of LM was achieved. This case shows that LM can be diagnosed by detecting EGFR mutation in CSF and EGFR tyrosine kinase inhibitors are effective for LM from EGFR mutant non-small cell lung cancer.

Keywords

References

  1. O'Meara WP, Borkar SA, Stambuk HE, Lymberis SC. Leptomeningeal metastasis. Curr Probl Cancer 2007;31:367-424. https://doi.org/10.1016/S0147-0272(07)00067-0
  2. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39. https://doi.org/10.1056/NEJMoa040938
  3. Tokumo M, Toyooka S, Kiura K, Shigematsu H, Tomii K, Aoe M, et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 2005;11:1167-73.
  4. Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM, et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 2006;24:4517-20. https://doi.org/10.1200/JCO.2006.06.6126
  5. Choong NW, Dietrich S, Seiwert TY, Tretiakova MS, Nallasura V, Davies GC, et al. Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation. Nat Clin Pract Oncol 2006;3:50-7. https://doi.org/10.1038/ncponc0400
  6. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982;49:759-72. https://doi.org/10.1002/1097-0142(19820215)49:4<759::AID-CNCR2820490427>3.0.CO;2-7
  7. Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999;5:3394-402.
  8. Kim MK, Lee KH, Lee JK, Choi JH, Hyun MS. Gefitinib is also active for carcinomatous meningitis in NSCLC. Lung Cancer 2005;50:265-9. https://doi.org/10.1016/j.lungcan.2005.05.022
  9. Katayama T, Shimizu J, Suda K, Onozato R, Fukui T, Ito S, et al. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 2009;4:1415-9. https://doi.org/10.1097/JTO.0b013e3181b62572
  10. Lee KY, Kim HJ, Kim SJ, Yoo GH, Kim WD, Oh SY, et al. PNA-mediated PCR clamping for the detection of EGFR mutations in non-small cell lung cancer. Tuberc Respir Dis 2010;69:271-8. Korean. https://doi.org/10.4046/trd.2010.69.4.271
  11. Kim HJ, Oh SY, Kim WS, Kim SJ, Yoo GH, Kim WD, et al. Clinical investigation of EGFR mutation detection by pyrosequencing in lung cancer patients. Oncol Lett 2013;5:271-6. https://doi.org/10.3892/ol.2012.950
  12. Shingyoji M, Kageyama H, Sakaida T, Nakajima T, Matsui Y, Itakura M, et al. Detection of epithelial growth factor receptor mutations in cerebrospinal fluid from patients with lung adenocarcinoma suspected of neoplastic meningitis. J Thorac Oncol 2011;6:1215-20. https://doi.org/10.1097/JTO.0b013e318219aaae
  13. Kim HJ, Lee KY, Kim YC, Kim KS, Lee SY, Jang TW, et al. Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Lung Cancer 2012;75:321-5. https://doi.org/10.1016/j.lungcan.2011.08.005
  14. Kim HR, Lee SY, Hyun DS, Lee MK, Lee HK, Choi CM, et al. Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping. J Exp Clin Cancer Res 2013;32:50. https://doi.org/10.1186/1756-9966-32-50
  15. Aisner DL, Sams SB. The role of cytology specimens in molecular testing of solid tumors: techniques, limitations, and opportunities. Diagn Cytopathol 2012;40:511-24. https://doi.org/10.1002/dc.22820